Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This article outlines a targeted approach for optimal upper facial rejuvenation in male patients but presents no new clinical findings.

This article reports a case of rhabdomyolysis in a patient two hours after consuming the freshwater fish Mylossoma duriventre, suggesting a possible link to Haff disease from an unidentified toxin.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

This study demonstrated that sodium valproate accelerates skin healing and reduces necrosis in a rat model of skin flap potentially through mechanisms involving GABA and histone deacetylase pathways.

This study reported that anti-androgens combined with lifestyle modifications were more effective than metformin and lifestyle in reducing hirsutism and certain hormonal measures in women with PCOS, but they were not more effective than a placebo combined with lifestyle changes.

This report presents a case of familial male-limited precocious puberty with a novel LHCGR gene mutation, where a boy responded well to treatment with bicalutamide and anastrozole.

This review discusses idiopathic hirsutism and suggests that combination treatment, including androgen suppression and cosmetic methods, is most effective, but notes that its pathogenesis remains unclear.

This article proposes naming the visual identification of androgenic alopecia in COVID-19 patients as the "Gabrin sign" to indicate higher risk for severe symptoms, but reports no new clinical results.

This case report describes a 4-year-old boy with autism and a rare condition causing precocious puberty, where treatment for hyperandrogenism unexpectedly intensified his aggressive behavior.

In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer.

This review summarizes current knowledge on the diagnosis and treatment of hirsutism but provides no new clinical results.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This article reviews the use of anti-androgens for dermatological conditions linked to androgen involvement and reports encouraging clinical experiences in females, with use in males limited to specific conditions due to toxicity concerns.

In this study, researchers developed a new human in vitro model for male androgenetic alopecia that replicates key features of the disorder, providing an effective platform for studying hair loss mechanisms and testing potential treatments.

This paper argues that androgenetic alopecia in transgender and gender-diverse individuals is clinically significant, suggesting individualized and gender-affirming treatment approaches, with oral minoxidil as a key therapy.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

In this systematic review, researchers found that injectable therapies, including agents like dutasteride and multivitamin formulations, may offer cosmetic benefits for androgenetic alopecia; however, evidence is limited by small study sizes, varied methods, and short follow-up periods, necessitating standardized trials for routine use recommendations.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This study discusses the use of low-dose oral minoxidil for hair loss, noting that while it is popular and considered safe, it can mimic Cantú syndrome effects such as hypertrichosis and pericardial effusion, necessitating careful monitoring and caution during prescription.

This study compared the effectiveness of combined oral contraceptives and antiandrogens for treating women with polycystic ovarian syndrome in late reproductive age.

In this study, a topical hair growth serum containing ingredients like procapil and redensyl was found to be safe and effective for subjects with androgenic alopecia, significantly improving hair density, thickness, and Anagen:Telogen ratio after 120 days, with no observed adverse effects.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

This study found that among women with female pattern hair loss, higher self-esteem is significantly associated with lower body image concerns and greater self-compassion.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This review discusses the clinical manifestations and management options for polycystic ovary syndrome and reports no new results, emphasizing the potential of herbal therapies and highlighting concerns with chemical anti-androgen drugs.

In this study, the stability properties of various active pharmaceutical ingredients (APIs) were characterized, revealing how factors like pressure and water sensitivity influence their intrinsic stability and potential degradation.